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Purpose: To investigate the pharmacokinetics of of a developed metoprolol and a reference standard 
(Mepressor®). 
Methods: Metoprolol tartrate-loaded Eudragit® FS microparticles were formulated and compressed into 
tablets. The tablets were tested for their physicochemical properties according to United States 
Pharmacopoeia (USP) criteria. In vivo studies of the formulations were carried out in 28 young healthy 
fasting male volunteers based on a randomized open label 4×4 crossover study design with a washout 
period of 7 days. 
Results: In vitro tests showed that the developed and reference standard of metoprolol tablets met 
compendia (USP) requirements. Zero order release of drug was observed from all the tablets. In vivo 
data demonstrated that there were significant (p < 0.05) differences in tmax, Cmax, MRT, AUC0−t, and 
AUC0–∞ between the reference and test  (developed) formulations. However, the 90 % class interval for 
the mean ratios of the ln-transformed Cmax, AUC0-t and AUC0-α for the reference, T1, T2, and T3 lied in 
the bioequivalence range (80 to 125 %) indicating bioequivalence between the compared formulations. 
Conclusion: It can be concluded from this single-dose study that the reference and test (developed) 
formulations met the predetermined criteria for bioequivalence in young healthy fasting male human 
subjects as the bioequivalence factor lie in the pre-determined limits for bioequivalence. Thus, the two 
formulations can be considered bioequivalent. 
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INTRODUCTION 
 
β-blockers, oxprenolol and metoprolol are 
well absorbed in the colon as well as in the 
small intestine. Thus, these drugs are good 
candidates for delivery to colon [1]. 
Metoprolol is used in the management of 
cardiovascular disorders such as 
hypertension and angina pectoris. It is 
completely absorbed in the intestine after oral 
administration but exhibits 50 % 
bioavailability due to extensive first pass 
effect [2]. The mean time to reach maximum 
plasma concentration and mean elimination 
half life for metoprolol after oral dosing are 2 
h and 4 h, respectively. Based on these 
parameters, metoprolol is administered 3-4 
times daily [3,4] which makes it a good 
candidate for formulation into extended and 
targeted release dosage form to decrease 
dosing frequency. 
 
Eudragit® polymers are commercial pH-
dependent co-polymers, are available in 
various ionic grades and have been approved 
by the Food and Drug Administration (FDA) 
for colonic drug delivery. Moreover, these 
polymers also act as both binders and 
coating materials [5]. Eudragit® FS, a 
potential pH-dependent carrier for colonic 
drug delivery, which retards drug release in 
stomach and small intestine, is a copolymer 
of methacrylic acid, methyl methacrylate and 
methyl acrylate [6]. 
 
Based on these considerations, this study 
was designed to develop suitable metoprolol 
- Eudragit® FS extended and targeted release 






Metoprolol tartrate was a gift from Novartis 
Pharmaceuticals, Karachi, Pakistan. 
Eudragit® FS was purchased from Rohm 
Pharma, Darmstadt, Germany. Metoprolol 
tartrate reference tablets (Mepressor® 200 
mg, Novartis Pharmaceuticals, Karachi, 
Pakistan) was purchased from Survaid 
Pharmacy, Lahore, Pakistan. Light liquid 
paraffin, acetone, n-hexane, and other 
chemicals of analytical grade were procured 
from Merck, Germany, and were used as 
received. 
 
Preparation of test tablets 
 
Metoprolol (1 g) and the copolymer, i.e., 
Eudragit® FS  (1, 1.5 or 2 g) were dissolved 
in acetone (20 ml) using a magnetic stirrer 
(rotating at 450 rpm) to prepare drug-polymer 
solution. Light liquid paraffin (40 ml) solution 
containing Span 80 (0.2 g) was added to the 
drug-polymer solution with continuous stirring 
for 4 h at room temperature (32 °C). 
Following complete removal of acetone, the 
resultant microparticles were harvested by 
filtration under vacuum. The microparticles 
were washed three times with n-hexane (100 
ml) and dried in an oven at 40 °C for 48 h. 
The microparticles (in drug/polymer ratios of 
1:1, 1:1.5 or 1:2, w/w) were directly 
compressed to tablets coded T1, T2 and T3, 
respectively, each tablet containing 200 mg 
of metoprolol. 
 
In vitro tests of tablets 
 
Evaluation of the weight variation, tablet 
hardness, friability, disintegration and 
dissolution of the reference and test tablets 
were performed.  
 
Six tablets were tested for disintegration in 
0.1M HCl for 2 h by using a USP basket rack 
assembly and then in phosphate buffer pH 
6.8. In vitro dissolution test was conducted by 
sequential pH change method using USP 
dissolution apparatus II to simulate 
gastrointestinal conditions. Three different 
dissolution media were used, namely, 0.1M 
hydrochloric acid (pH 1.2) for 2 h, phosphate 
buffer (pH 4.5) for 2 h and phosphate buffer 
(pH 7.0) for 8 h. The volume of the 
dissolution medium used in each case was 
900 ml which was stirred at 50 rpm and 37 ± 
0.5 °C. Dissolution samples (5 ml) were 
withdrawn at 0, 1, 2, 3, 4, 6, 8, 10 and 12 h, 
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filtered through a 0.45 µm filter and analyzed 
as described previously [7]. To assess the 
mode of in vitro drug release from the 
formulations, the release data were fitted to 
zero-order, first-order, Higuchi and 
Korsmeyer–Peppas models [7,8]. 
 
Pharmacokinetic tests – protocol and 
subject criteria 
 
In vivo study was carried out at the Centre for 
Bioequivalence Studies, Faculty of Pharmacy 
and Alternative Medicines, the Islamia 
University of Bahawalpur, Bahawalpur, 
Pakistan, after obtaining ethical approval. 
The heart rate, blood pressure and 
respiration rate of the human subjects were 
continuously monitored. Also, ECG and 
blood, urine and hepatic tests were 
performed on a regular basis. The subjects 
were questioned regarding adverse effects 
experienced during the study (including 
washout periods) and the responses were 
recorded on an appropriate format. The 
principles of Helsinki Declaration [9] and 
Good Clinical Practice [10] were observed in 
the conduct of the study. Based on the 
outcomes of ECG and blood, urine and 
hepatic tests, twenty eight young healthy 
fasting male human volunteers {age 23.5 ± 
4.2 years (range 20 - 30 years), weight 66.7 ± 
9.5 kg (range 59 - 82 kg)} were randomly 
recruited for a four-way, four periods, single 
dose, randomized crossover study. The 
subjects, who were non-smokers and non-
alcoholic, gave their fully informed consent, 
and also accepted to cooperate fully 
throughout the duration of the study. They 
were advised to avoid the use of any drug 14 
days prior to the commencement of the 
study.  
 
Following an overnight fast, the volunteers 
received the test and reference (standard) 
tablets with 200 ml of water in a randomized 
order with a washout period of 7 days. The 
volunteers were provided with a standard 
hunch (low fat meal, FDA approved) [11] 12 h 
pre-dose and 4 h post-dose fasting. Following 
oral administration of the tablets, venous 
blood samples (5 ml, after first 0.5 ml had 
been discarded) from antecubital vein were 
collected via an intravenous cannula (20 
gauge) in heparinized-glass tubes (containing 
200 µl heparin) at predetermined time 
intervals (0, 1, 2, 3, 4, 6, 8, 10 and 12 h) for 
each protocol. The samples were 
immediately centrifuged at 1000 g for 10 min 
at room temperature (32 °C) to obtain plasma 
that was stored in labelled Eppendorf tubes in 
a freezer at -20 °C until quantitative bio-
analysis by HPLC. 
 
Analysis of metoprolol samples by HPLC 
 
The quantitative determination of metoprolol 
tartrate in dissolution and plasma samples 
was performed by HPLC method [3,12]. The 
HPLC (Isocratic HPLC, Agilent, California, 
USA) was connected to UV/Vis detector 
(Agilent, USA) operated at 273 nm and 
Hypersil ODS-C18 column (250 mm × 4.6 
mm internal diameter, particle size 5 mm; 
Agilent, USA) operated at 27 °C. The HPLC 
system was operated with ChemStation 
software. A degassed mixture of acetonitrile 
and triple distilled water containing 0.4 % of 
triethylamine (pH adjusted to 3.6 with 5 % 
ortho-phosphoric acid) in the ratio of 15:85 
was employed as mobile phase, and eluted 
at a flow rate of 1.0 mL/min. Total run time for 
each sample was set at 15 min. Tramadol 
hydrochloride, as the internal standard, 
showed no interference with the peaks of 
metoprolol. The validation parameters [3.12] 
for the method were also determined (Table 
1) according to international guidelines [13]. 
A calibration curve (n = 7) was constructed 
for the determination of metoprolol in the 
concentration of 20 – 200 ng/ml.  
 
Data analysis  
 
Experimental results were expressed as 
mean ± standard deviation (SD). Based on 
the non-compartment model approach, the 
values of Cmax (maximum drug concentration 
in plasma), tmax (time to reach peak 
concentration), AUC (area under the curve), 
Ke (elimination rate constant), t1/2 (biological 
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half life) and MRT (mean residence time) 
were measured from plasma metoprolol 
concentration versus time profiles for each 
volunteer, using Microsoft Excel, 2007 [1]. 
 
The significance of difference between 
various pharmacokinetic parameters was 
evaluated by Analysis of Variance (ANOVA) 
using software, SPSS version 13.0 [1]. The 
level of significance was set at 0.05. As same 
doses of reference and test formulations 
were given, the relative bioavailability (F %) 
was calculated by dividing ln-transformed 
Cmax, AUC0-t and AUC0.∞ of test formulation 
with the Cmax, ln-transformed AUC0-t and 
AUC0.∞ of reference formulation, respectively.  
Two compared formulations were considered 
bioequivalent if the 90% class intervals (CIs) 






The coefficient of regression (R2) of 
metoprolol calibration curve was 0.9986. 
Intra- and inter-day RSD for metoprolol in 
plasma was < 4 % while intra- and inter-day 
accuracy was > 95 %, as shown in Table 1. 
These values indicate that the method used 
has high repeatability and precision for 
metoprolol analysis. 
 
Physicochemical properties of metoprolol 
tablets 
 
The weight variation, hardness, friability, 
disintegration, and dissolution for all 
formulations were within allowed limits of 
USP [7]. 
 
Copolymer concentration influenced the 
release behavior of metoprolol tablets. As the 
polymer ratio was increased from T1 to T3, 
the release of metoprolol from formulations 
decreased. Drug release was very slow in pH 
1.2 and pH 4.5 dissolution media; in contrast, 
cumulative drug release range from about 56 
– 71 % in pH 7.0 media, regardless of the 
polymer concentration. The best-fit kinetic 
model for the dissolution data of the test 
formulations was zero order followed by 
Higuchi and then first order model [7]. 
 
Tolerability of the formulations 
 
During in vivo study, physical observation by 
clinician as well as biochemical and 
hematological tests indicate that there were 
no significant adverse effects asa result of 
the administration of any of the formulations, 
except for mild gastrointestinal disturbance 
with the reference formulation in one 
volunteer at the second stage of the study. 
However, this was not linked to the drug. 
Also, there were no significant changes in 
blood, urine and hepatic parameters during 
the study for any of the formulations. The 
ECG of all the subjects was normal before 
and after the study.  
 
Plasma metoprolol concentration versus time 
profiles of the reference and test formulations 
are presented in Figure 1 while the derived 
 
Table 1:  Intra- and inter-day precision and accuracy profiles (mean ± SD, n = 3) for HPLC method used in 
sample analysis 
 















R.S.D. c  (%) 
Accuracyb 
(Bias, %) 
20 19.87 ± 0.50 2.53 -0.63 19.87 ± 1.29 6.47 -0.63 
100 100.79 ± 0.44 0.43 0.79 100.79 ± 1.37 1.36 0.79 
200 199.22 ± 0.51 0.26 -0.39 198.88 ± 0.68 0.34 -0.56 
 
b Accuracy (bias, %) = (detected concentration – added concentration) / (added concentration) × 100 
c Precision (R.S.D, %) – (standard deviation / mean) x 100 
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pharmacokinetic parameters are shown in 
Table 2. Cmax (mean ± SD, µg/ml) for the 
reference, T1, T2, and T3 was 190.64 ± 
11.84, 144.18 ± 14.55, 133.50 ± 13.65 and 
129.07 ± 17.13, respectively, while AUC0-t 
(µg.h/ml) was 1423.46 ± 21.81, 849.89 ± 
19.86, 857.04 ± 14.86 and 823.82 ± 13.28, 
respectively. AUC0-α (µg.h/ml) for the 
reference, T1, T2, and T3 was 1675.18 ± 
19.57, 927.35 ± 20.09, 1028.79 ± 24.93 and 
999.54 ± 17.69, respectively, and tmax (h) 4.00 
± 0.45, and 6.00 ± 0.38, 6.00 ± 0.50 and 6.00 
± 0.43, respectively. The bioavailability of the 
reference standard was significantly higher (p 
< 0.05) that of the test samples. MRT data 
indicate that the test formulations remained 



























Figure 1:  Plasma metoprolol concentration versus 
time plots after administration of 200 mg dose 




To analyze bioequivalence, the 90 % class 
intervals for the ratios of the ln-transformed 
Cmax, AUC0-t and AUC0-α for the reference, 
T1, T2, and T3 were evaluated and are 
presented in Table 2. These results lie in the 
pre-determined range of bioequivalence (80 
to 125 %), indicating bioequivalence between 




Copolymer concentration influenced the 
release behavior of metoprolol tablets. This is 
due to the acid-resistant property of the 
polymer matrix which increases as polymer 
content rose, leading to decrease in 
metoprolol [7]. This is a consequence of the 
fact that higher polymer concentration 
produces larger particles with proportionately 
less drug. The slower drug release at pH 1.2 
and pH 4.5 dissolution media is a result of the 
fact that Eudragit® FS is pH-sensitive 
copolymer that only begins to dissolved at pH 
6.0 [7]. In pH 7.0 medium, the polymer readily 
dissolves, creating channels in the 
microparticle coating and thus, facilitating 
faster drug release [7].  
 
Tmax among all the developed (test) 
formulations was not significantly (p > 0.05) 
different from each other but were 
significantly (p < 0.05) less than that of the 
reference. The significantly lower values of 
Cmax, AUC0-t and AUCt-∞ of the test 
formulations, compared to those of the 
reference can be attributed to the coclonic 
release pattern of the latter, since after 
departure from the stomach, the colonic 
coating prevents drug release for an 
additional 2 h approximately, compared to the 
reference formulation. This is buttressed by 
the higher values of tmax and MRT fortest 
formulations.  
 
The reference formulation has significantly 
different bioavailability from that of the test 
formulations. Metoprolol is a basic drug. 
Since basic drugs exhibit higher absorption in 
basic conditions such as the colon,  
bioavailability from test (colonic) formulations 
should be higher than that of the reference 
but the results indicate the reverse. 
 
The possible reason for this unexpected 
result may be the loss of unreleased drug 
through feces due to stronger bonding 
between metoprolol and the polymer. 
However, stool analysis would need to be 
conducted to confirmthis. Consequently, it is 
one of the limitations of this study that the 
stool analysis and frequency has not been 
studied. However, this limitation will be sorted 
out in the future projects. 
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Table 2:  Pharmacokinetic parameters and comparative bioavailability (standard deviation or range in 
brackets) of sustained release tablets (reference) and developed colonic tablets (T1, T2 and T3) of 
metoprolol tartrate following administration of a single oral dose of 200 mg to 28 healthy human volunteers 
 
Parameter Reference T1 T2 T3 
tmax (h) 4 (0.45) 6 (0.38) 6 (0.5) 6 (0.43) 
MRT (h) 5.78 (0.43) 6.72 (0.43) 7.03 (0.43) 7.23 (0.43) 
Cmax (µg/ml) 190.64 (11.84) 144.18 (14.55) 133.50 (13.65) 129.07 (17.13) 
AUC0-t (µg.h/ml) 
1423.46 
(21.81) 849.89 (19.86) 857.04 (14.86) 823.82 (13.28) 
AUC0-∞ (µg.h/ml) 
1675.18 
(19.57) 927.35 (20.09) 1028.79 (24.93) 999.54 (17.69) 
Ratio of Ln Cmax 
(%) (90% CI), 
range 
- 94.63 (93.91 – 95.34) 
93.16  
(92.45 - 93.87) 
92.45  
(91.58 - 93.32) 
Ratio of Ln 
AUC0-t   
(%) (90% CI) 
- 92.90 
(92.77 – 93.02) 
93.01  
(92.90 - 93.12) 
92.47  
(92.38 - 92.56) 
Ratio of Ln 
AUC0-∞   
(%) (90% CI) 
- 92.03  (91.93 – 92.14) 
93.43  
(93.32 - 93.54) 
93.04  
(92.95 - 93.14) 
 
Limitations of the study 
 
The bioavailability and pharmacokinetic study 
was carried out in 28 young healthy fasting 
male volunteers. To more closely simulate 
actual clinical situation, the study shouldd 
have been conducted in the fed state using a 
larger sample size and multiple dosing, as 
well as females, children, old and ill 
volunteers in the sample population. Stool 
analysis and frequency should also be 




It can be concluded from this single-dose 
study that the reference and test formulations 
met the predetermined criteria for 
bioequivalence in the young healthy fasting 
male human subjects as the bioequivalence 
factor lie in the pre-determined limits for 
bioequivalence. Thus the two formulations 
can be considered bioequivalent. The two 
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